Investors Urged to Join Class Action Against Mereo BioPharma Over Alleged Securities Fraud

On February 11, 2026, Levi & Korsinsky, LLP, a prominent law firm, alerted investors of a significant opportunity to join a class action lawsuit against Mereo BioPharma Group plc, trading on NASDAQ under the symbol MREO. The case revolves around accusations of securities fraud that reportedly occurred between June 5, 2023, and December 26, 2025.

The class action aims to recover financial losses experienced by investors during this timeframe, where misleading statements and concealed adverse facts may have severely impacted stock valuations. Notably, the firm emphasizes that any Mereo investor affected by these alleged misrepresentations can reach out for assistance.

Case Background

Levi & Korsinsky's lawsuit alleges that Mereo BioPharma made overwhelmingly positive comments about its clinical programs while simultaneously hiding critical facts regarding their effectiveness. Particularly, the Phase 3 clinical trials known as ORBIT and COSMIC fell short of achieving critical endpoints, which were supposed to measure the reduction of clinical fracture rates compared to control groups. On December 29, 2025, Mereo disclosed that neither trial reached statistical significance, despite earlier assertions of progress. This disclosure resulted in a dramatic plunge in the company's stock price, dropping from a closing market price of $2.31 on December 26 to just $0.29 by December 29, reflecting a staggering decline of over 87.7%.

Key Dates and Next Steps

For investors who suffered losses, it is crucial to act swiftly. The deadline to join the class action and request lead plaintiff status is set for April 6, 2026. Potential class members have the option to benefit from any eventual recovery without upfront costs or fees, making participation financially risk-free.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has earned its reputation over the years for successfully representing shareholders in complex securities litigation. With a record of securing hundreds of millions of dollars for clients, the firm operates with a dedicated team of over 70 professionals focused on delivering results in high-stakes cases. This demonstrates their capability in handling significant litigation in securities matters, consistently recognized as one of the leading firms in the realm of class-action lawsuits.

In the face of financial misconduct, having a seasoned legal team could be vital to recovering losses. Mereo investors looking to explore their rights and options are encouraged to contact the firm for more information. Interested parties can reach out via email or phone, ensuring they are supported throughout the process.

For additional details, prospective claimants are encouraged to fill out a submission form located on Levi & Korsinsky’s website, where they can engage directly with the team. This class action represents an opportunity for Mereo investors to stand up against potential wrongdoing and seek justice through legal action.

In conclusion, Mereo BioPharma's stock performance has raised red flags, and any investor who felt the impact of this downturn should not hesitate to investigate their options. Timing is of the essence, so interested individuals should take immediate action before the upcoming deadline, securing their chance to recover any significant losses incurred due to these alleged actions.